Dr. Reddy's Q1 FY27 Hit by Semaglutide API Challenges

What happened

Dr. Reddy's Laboratories reported consolidated revenue of INR 8,071 crores ($853 million) for Q1 FY27, down 5.6% year-over-year but up 7.4% sequentially. EBITDA came in at INR 1,009 crores ($107 million), resulting in an EBITDA margin of 12.5%. The quarter included a provision of INR 240 crores for inventory and other costs related to semaglutide API challenges. Excluding this provision, EBITDA margin would have been 15.4% and gross margin 49.4% instead of the reported 46.5%. Management attributed the lower profitability to semaglutide-related issues (including lower sales, rejected batches, lost production incentives, and associated costs), reduced lenalidomide sales, and impact from the Middle East conflict. The company had sold 180,000 semaglutide pens before halting supplies due to the API issue. Management said the base business, excluding lenalidomide, continued to grow at a double-digit rate across key geographies.

Why it matters

The semaglutide API issue represents a significant near-term headwind for Dr. Reddy's, compressing margins and disrupting a key growth product in the diabetes and weight-loss space. The INR 240 crore provision and lost production incentives highlight the financial cost of the quality setback. However, management's emphasis on double-digit growth in the base business (excluding lenalidomide) suggests underlying strength in other product lines. Investors should note that the company expects to resume semaglutide commercial supplies by November, with plans to deliver 6 million to 7 million pens between November and March, though this timeline carries execution risk. Management estimated the disruption cost the company about 3 million to 4 million pens in lost opportunity. The company has identified the root cause and expects testing to complete by the third week of September, with an estimated 80% to 90% probability of successful resolution.

Bigger picture

Semaglutide, a GLP-1 receptor agonist used for diabetes and weight management, is a highly competitive and fast-growing market. Dr. Reddy's entry into this space positions it alongside major players in the diabetes and obesity treatment segment. However, API quality issues can have cascading effects on generic drug manufacturers, impacting regulatory standing, customer relationships, and near-term profitability. The broader generic pharmaceutical industry faces ongoing margin pressures from pricing dynamics, competition, and regulatory scrutiny. Dr. Reddy's lenalidomide sales decline reflects the expected erosion as exclusivity periods fade and competition intensifies in key oncology generics. The company's ability to diversify revenue sources and maintain growth in its base business will be critical to offsetting these headwinds. The Middle East conflict also represents a geopolitical risk factor affecting operations and margins.

What to watch

Investors should monitor whether Dr. Reddy's successfully resolves the semaglutide API issue and resumes commercial supplies by November as planned. Watch for updates on testing completion (expected by the third week of September) and regulatory clearance. Track whether the company delivers the projected 6 million to 7 million semaglutide pens between November and March, as this will determine whether the growth opportunity can be recaptured. Monitor EBITDA margin trajectory in subsequent quarters to assess whether margins rebound toward management's high-teens target once semaglutide issues are resolved. Also watch for continued growth momentum in the base business, excluding lenalidomide, and any updates on the impact of the Middle East conflict on operations and margins.